Importantly, the activation of Akt and Erk1/2 plays critical role in the response of glioma cells to DCEF, since the using of specific inhibitor can decrease the activation of Erk1/2 or Akt and the directional migration. This evidence concerns the gene MAPK3 and central nervous system cancer.